To evaluate the clinical efficacy and safety of montelukast sodium in treating viral pediatric asthma
评价孟鲁司特钠治疗病毒性小儿哮喘的临床疗效及安全性

摘要

目的 探究为病毒性小儿哮喘患儿给予孟鲁司特钠治疗的效果与安全性。方法 选择2023年6月至2024年6月收治的68例病毒性哮喘患儿参与研究，对照组给予常规治疗，观察组给予孟鲁司特钠治疗。比较两组治疗效果。结果 观察组治疗有效率高于对照组，差异有统计学意义（P＜0.05）；观察组不良反应发生率低于对照组，差异有统计学意义（P＜0.05）。结论 孟鲁司特钠用于治疗病毒性小儿哮喘能够改善治疗效果，并具有较低的不良反应率，安全性较高。

Abstract

Objective To explore the effect and safety of montelukast sodium treatment in children with viral pediatric asthma.
Methods 68 children with viral asthma admitted from June 2023 to June 2024 were selected to participate in the study. The control group received conventional treatment, and the observation group received montelukast sodium treatment. To compare the treatment effects between the two groups.
Results The response rate was higher than the control group and statistically significant (P <0.05); the incidence of adverse effects in the observation group was lower than the control group and statistically significant (P <0.05).
Conclusion   Montelukast sodium for treating viral pediatric asthma can improve the treatment effect, with a low adverse reaction rate and a high safety rate.